Sample Page
Author:
Fennec Pharmaceuticals Inc.
Posted Date:
May 7, 2026
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
Fennec Pharmaceuticals Inc.
May 7, 2026
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
Fennec Pharmaceuticals Inc.
April 23, 2026
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
Fennec Pharmaceuticals Inc.
April 7, 2026
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fennec Pharmaceuticals Inc.
March 31, 2026
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Fennec Pharmaceuticals Inc.
March 24, 2026
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
Fennec Pharmaceuticals Inc.
March 18, 2026
Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
Fennec Pharmaceuticals Inc.
March 16, 2026
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
Fennec Pharmaceuticals Inc.
March 4, 2026
Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
Fennec Pharmaceuticals Inc.
February 20, 2026
